Medicines Law & Policy

Medicines Law & Policy brings together legal and policy experts in the field of access to medicines, international law, and public health. We provide policy and legal analysis, best practice models and other information that can be used by governments, non-governmental organisations, product development initiatives, funding agencies, UN agencies and others working to ensure the availability of effective, safe and affordable medicines for all.

Articles from this Author

European Parliament’s amendments make the Regulation for EU-wide compulsory licensing difficult to use and need to be rolled back

Intervention at Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response, 9th...

Commission report on competition enforcement in the pharmaceutical sector

ML&P’s Statement at the Intergovernmental Negotiating Body on a pandemic accord

The Urgency of Compulsory Licensing Provision for Transfer of Technology in the Pandemic Treaty: A Case Study on the WHO mRNA Hub

Current drafts of the WHO Pandemic Accord lack a provision for access to knowhow/trade secrets. We drafted one.

Thanks to the European Commission, Biogen can extend Tecfidera monopoly for at least two more years.

New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments

Medicines Law & Policy

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

This work is licensed under Creative Commons. You are free to share, with attribution and without changes, for non-commercial purposes.

Technical Briefing Papers

Our Work on Covid-19

Our Blog

The TRIPS Flexibilities Database